Evidence map›Paper›PMID 25466928›Full record

ArticleBMC infectious diseases2014

Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patients.

Mohamed A M Salih, Michaela Fakiola, Mohamed H Abdelraheem, Brima M Younis, Ahmed M Musa, Ahmed M ElHassan, Jenefer M Blackwell, Muntaser E Ibrahim, Hiba S Mohamed

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Commentary on the Issue ofVeterinary sciences · 2025
    Article
  3. Immune response to viscerotropicFrontiers in immunology · 2024
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Mohamed A M SalihInstitute of Endemic Disease, University of Khartoum, P. O. Box 102, Khartoum, Sudan. msalih56@hotmail.com.
Michaela FakiolaDepartment of Medicine and Department of Pathology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK. mf300@cam.ac.uk.
Mohamed H AbdelraheemInstitute of Endemic Disease, University of Khartoum, P. O. Box 102, Khartoum, Sudan. mohammed2003w@hotmail.com.
Brima M YounisInstitute of Endemic Disease, University of Khartoum, P. O. Box 102, Khartoum, Sudan. brimamusa@hotmail.com.
Ahmed M MusaInstitute of Endemic Disease, University of Khartoum, P. O. Box 102, Khartoum, Sudan. amudawi@hotmail.com.
Ahmed M ElHassanInstitute of Endemic Disease, University of Khartoum, P. O. Box 102, Khartoum, Sudan. elhassan_85@yahoo.com.
Jenefer M BlackwellDepartment of Medicine and Department of Pathology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK. jblackwell@ichr.uwa.edu.au.
Muntaser E IbrahimInstitute of Endemic Disease, University of Khartoum, P. O. Box 102, Khartoum, Sudan. mibrahim@iend.org.
Hiba S MohamedInstitute of Endemic Disease, University of Khartoum, P. O. Box 102, Khartoum, Sudan. hibasalah@iend.org.
University of Khartoum · SDThe Kids Research Institute Australia · AUUniversity of Cambridge · GB

Funding

Wellcome Trust 100715
6 · The paper itself

Abstract

backgroundLittle is known about the parasite/host factors that lead to Post Kala-azar Dermal Leishmaniasis (PKDL) in some visceral leishmaniasis (VL) patients after drug-cure. Studies in Sudan provide evidence for association between polymorphisms in the gene (IFNGR1) encoding the alpha chain of interferon-γ receptor type I and risk of PKDL. This study aimed to identify putative functional polymorphisms in the IFNGR1 gene, and to determine whether differences in expression of interferon-γ (IFNG) and IFNGR1 at the RNA level are associated with pathogenesis of VL and/or PKDL in Sudan.

methodsSanger sequencing was used to re-sequence 841 bp of upstream, exon1 and intron1 of the IFNGR1 gene in DNA from 30 PKDL patients. LAGAN and SYNPLOT bioinformatics tools were used to compare human, chimpanzee and dog sequences to identify conserved noncoding sequences carrying putative regulatory elements. The relative expression of IFNG and IFNGR1 in paired pre- and post-treatment RNA samples from the lymph nodes of 24 VL patients, and in RNA samples from skin biopsies of 19 PKDL patients, was measured using real time PCR. Pre- versus post-treatment expression was evaluated statistically using the nonparametric Wilcoxon matched pairs signed-rank test.

resultsTen variants were identified in the 841 bp of sequence, four of which are novel polymorphisms at -77A/G, +10 C/T, +18C/T and +91G/T relative to the IFNGR1 initiation site. A cluster of conserved non-coding sequences with putative regulatory variants was identified in the distal promoter of IFNGR1. Variable expression of IFNG was detected in lymph node aspirates of VL patients before treatment, with a marked reduction (P = 0.006) in expression following treatment. IFNGR1 expression was also variable in lymph node aspirates from VL patients, with no significant reduction in expression with treatment. IFNG expression was undetectable in the skin biopsies of PKDL cases, while IFNGR1 expression was also uniformly low.

conclusionsUniformly low expression of IFN and IFNGR1 in PKDL skin biopsies could explain parasite persistence and is consistent with prior demonstration of genetic association with IFNGR1 polymorphisms. Identification of novel potentially functional rare variants at IFNGR1 makes an important general contribution to knowledge of rare variants of potential relevance in this Sudanese population.

Indexed as

AdolescentAdultChildChild, PreschoolFemaleHumansInterferon-gammaInterferon gamma ReceptorLeishmaniasis, CutaneousLeishmaniasis, VisceralMalePolymorphism, GeneticPromoter Regions, GeneticReceptors, InterferonRNA, MessengerSkinInterferon-gammaInterferon gamma ReceptorReceptors, InterferonRNA, Messenger

Identifiers

PMID25466928
PMCPMC4265480
OpenAlexW2103179909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.